Advertisement

Topics

OctreoPharm Sciences GmbH Company Profile

04:38 EST 21st November 2018 | BioPortfolio

OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control of tumors. Current shareholder of OctreoPharm Sciences GmbH are Eckert & Ziegler AG, VC Funds Technology managed by IBB Berlin GmbH, KfW Mittelstandsbank, Eckert Life Science Accelerator GmbH, OctreoPharm (Holding) GmbH and the Chinese investor Shaanxi Xinyida Investment Co. Ltd.


News Articles [706 Associated News Articles listed on BioPortfolio]

New financing round at oncgnostics GmbH close

The life sciences company oncgnostics GmbH was able to double its investment of 750,000 euros following the very rapid and successful completion of its second crowd investing campaign on Seedmatch. A...

Urovant Sciences nets $130.2mm in Nasdaq IPO

Roivant Sciences GMBH's urology-focused subsidiary Urovant Sciences Ltd. netted $130.2mm in an initial public offering of 10mm shares at $14 apiece (the low end of its $14-16 range).

Urovant Sciences files for Nasdaq IPO

Roivant Sciences GMBH's urology-focused subsidiary Urovant Sciences Ltd. filed for an initial public offering on Nasdaq.

LenioBio GmbH and Fraunhofer IME to Advance Novel Protein Discoveries Through a License Agreement

DUSSELDORF and AACHEN, Germany, August 1, 2018 /PRNewswire/ -- Life sciences startup LenioBio GmbH and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME Read more...

Urovant gains global rights to ICI's gene therapy for OAB

Roivant Sciences GMBH's Urovant Sciences Ltd. licensed exclusive worldwide development, manufacturing, and commercialization rights to Ion Channel Innovations LLC's naked DNA gene therapy hMaxi-K, for...

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...

Roivant Sciences raises $200mm in private placement

Roivant Sciences GMBH raised $200mm in a private placement financing ($7bn post-money valuation) with new investors NovaQuest Capital Management, RTW Investments and other large institutional asset ma...

Laufende Fusionskontrollverfahren: Bruker Daltonik GmbH, Bremen (D); Erwerb einer Mehrheitsbeteiligung von 80% an der HAIN LIFESCIENCE GmbH, Nehren (D);

Datum der Anmeldung:28.08.2018Aktenzeichen:B3-128/18Unternehmen:Bruker Daltonik GmbH, Bremen (D); Erwerb einer Mehrheitsbeteiligung von 80% an der HAIN LIFESCIENCE GmbH, Nehren (D);Produktmärkte:in.....

Clinical Trials [245 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

M-learning to Improve Professional Competencies in Health Sciences

The aim of this study is to investigate whether a mobile application is useful for improving knowledge about professional competencies in students enrolled in Health Sciences degrees.

XC8 in the Treatment of Patients With Bronchial Asthma

A multicenter, double-blind, randomized, parallel-group comparative Phase II clinical study to assess the efficacy and safety of different doses of XC8 vs Placebo in patients with partly c...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Cognitive Rehabilitation With C8 Sciences

C8 sciences program is a cognitive training program mainly developed for the students, and the effectiveness is well established. The aim of this trial is to assess clinical efficacy of th...

Companies [1599 Associated Companies listed on BioPortfolio]

OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control ...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

Medea AV GmbH

medea AV GmbH is the manufacturer of the medeaLAB Imaging Systems. 20 years of experience in image processing contributed to our image analysis systems for research and industry. We develop specialize...

Praher Beteiligungs GmbH

The vision of the company founder Ludwig Praher to produce better and better products of high-grade plastics was the basis for sound growth. Under the direction of Ing. Winfried Praher and Ewald Prahe...

Ormecon GmbH

Ormecon GmbH, with its location in Ammersbek/Germany, is the headquarter of Ormecon International. Ormecon GmbH was originally founded as "Ormecon Chemie GmbH & Co. KG" in 1996, as a 100% subsidiary o...

More Information about "OctreoPharm Sciences GmbH" on BioPortfolio

We have published hundreds of OctreoPharm Sciences GmbH news stories on BioPortfolio along with dozens of OctreoPharm Sciences GmbH Clinical Trials and PubMed Articles about OctreoPharm Sciences GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OctreoPharm Sciences GmbH Companies in our database. You can also find out about relevant OctreoPharm Sciences GmbH Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record